| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Animal Models |




From the Departments of Dermatology*
and
Pathology,
Emory University School of
Medicine, Atlanta, Georgia; the Department of
Surgery,
Childrens Hospital, Harvard
Medical School, Boston, Massachusetts; the Department of
Pathology,§
Beth Israel Deaconness Medical
Center, Harvard Medical School, Boston, Massachusetts; and the
Department of Genetics and Pathology,¶
Rudbeck
Laboratory Uppsala University, Uppsala, Sweden
Vascular endothelial growth factor (VEGF or vascular permeability factor) is an important angiogenic factor that is up-regulated in numerous benign and malignant disorders, including angiosarcoma, hemangiomas, and solid tumors. To determine the functional role of VEGF in the development of endothelial tumors, we expressed primate VEGF 121 in an endothelial cell line, MS1, derived from primary murine cells by immortalization with a temperature-sensitive SV40 large T antigen. This cell line expresses the VEGFR-2 (Flk-1/Kdr) receptor for VEGF. Expression of VEGF 121 led to the development of slowly growing endothelial tumors, which were histologically well-differentiated angiosarcomas. The angiosarcomas generated from MS1 VEGF cells demonstrated up-regulation of the VEGF receptors VEGFR-2 and VEGFR-1 (Flt-1) in vivo compared with benign hemangiomas generated from MS1 cells. Treatment of these cells with the VEGFR-2 tyrosine kinase inhibitor SU 1498 led to decreased expression of ets-1, a transcription factor which has been shown to be stimulated by VEGF. These results suggest that high level expression of VEGF in endothelial cells may result in malignant transformation. This transformation process likely involves both autocrine and paracrine pathways.
This article has been cited by other articles:
![]() |
N. E. Vlahakis, B. A. Young, A. Atakilit, A. E. Hawkridge, R. B. Issaka, N. Boudreau, and D. Sheppard Integrin {alpha}9beta1 Directly Binds to Vascular Endothelial Growth Factor (VEGF)-A and Contributes to VEGF-A-induced Angiogenesis J. Biol. Chem., May 18, 2007; 282(20): 15187 - 15196. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Schumacher, R. P.M. Dings, J. Cosin, I. V. Subramanian, N. Auersperg, and S. Ramakrishnan Modulation of Angiogenic Phenotype Alters Tumorigenicity in Rat Ovarian Epithelial Cells Cancer Res., April 15, 2007; 67(8): 3683 - 3690. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Yau, C. Kim, G. Li, Y. Zhang, S. Fazel, D. Spiegelstein, R. D. Weisel, and R.-K. Li Enhanced Angiogenesis With Multimodal Cell-Based Gene Therapy Ann. Thorac. Surg., March 1, 2007; 83(3): 1110 - 1119. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kim, R.-K. Li, G. Li, Y. Zhang, R. D. Weisel, and T. M. Yau Effects of Cell-Based Angiogenic Gene Therapy at 6 Months: Persistent Angiogenesis and Absence of Oncogenicity Ann. Thorac. Surg., February 1, 2007; 83(2): 640 - 646. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takeda and G.-H. Fong Prolyl Hydroxylase Domain 2 Protein Suppresses Hypoxia-Induced Endothelial Cell Proliferation Hypertension, January 1, 2007; 49(1): 178 - 184. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Dursun, Z. He, H. Somerset, D.-J. Oh, S. Faubel, and C. L. Edelstein Caspases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis Am J Physiol Renal Physiol, September 1, 2006; 291(3): F578 - F587. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Yau, C. Kim, G. Li, Y. Zhang, R. D. Weisel, and R.-K. Li Maximizing Ventricular Function With Multimodal Cell-Based Gene Therapy Circulation, August 30, 2005; 112(9_suppl): I-123 - I-128. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Yau, G. Li, Y. Zhang, R. D. Weisel, D. A.G. Mickle, and R.-K. Li Vascular Endothelial Growth Factor Receptor Upregulation in Response to Cell-Based Angiogenic Gene Therapy Ann. Thorac. Surg., June 1, 2005; 79(6): 2056 - 2063. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-E. Neagoe, C. Lemieux, and M. G. Sirois Vascular Endothelial Growth Factor (VEGF)-A165-induced Prostacyclin Synthesis Requires the Activation of VEGF Receptor-1 and -2 Heterodimer J. Biol. Chem., March 18, 2005; 280(11): 9904 - 9912. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hida, Y. Hida, D. N. Amin, A. F. Flint, D. Panigrahy, C. C. Morton, and M. Klagsbrun Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities Cancer Res., November 15, 2004; 64(22): 8249 - 8255. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tamura, M. Oda, Y. Tsunezuka, I. Matsumoto, K. Kawakami, and G. Watanabe Vascular endothelial growth factor expression in metastatic pulmonary tumor from colorectal carcinoma: Utility as a prognostic factor J. Thorac. Cardiovasc. Surg., October 1, 2004; 128(4): 517 - 522. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Cerimele, L. F. Brown, F. Bravo, G. M. Ihler, P. Kouadio, and J. L Arbiser Infectious Angiogenesis: Bartonella bacilliformis Infection Results in Endothelial Production of Angiopoetin-2 and Epidermal Production of Vascular Endothelial Growth Factor Am. J. Pathol., October 1, 2003; 163(4): 1321 - 1327. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Govindarajan, X. Bai, C. Cohen, H. Zhong, S. Kilroy, G. Louis, M. Moses, and J. L Arbiser Malignant Transformation of Melanocytes to Melanoma by Constitutive Activation of Mitogen-activated Protein Kinase Kinase (MAPKK) Signaling J. Biol. Chem., March 7, 2003; 278(11): 9790 - 9795. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ohta, N. Ohta, M. Tamura, J. Wu, Y. Tsunezuka, M. Oda, and G. Watanabe Vascular Endothelial Growth Factor Expression in Airways of Patients With Lung Cancer* : A Possible Diagnostic Tool of Responsive Angiogenic Status on the Host Side Chest, May 1, 2002; 121(5): 1624 - 1627. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Rissanen, I. Vajanto, M. O. Hiltunen, J. Rutanen, M. I. Kettunen, M. Niemi, P. Leppanen, M. P. Turunen, J. E. Markkanen, K. Arve, et al. Expression of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 (KDR/Flk-1) in Ischemic Skeletal Muscle and Its Regeneration Am. J. Pathol., April 1, 2002; 160(4): 1393 - 1403. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. O. Ogunshola, A. Antic, M. J. Donoghue, S.-Y. Fan, H. Kim, W. B. Stewart, J. A. Madri, and L. R. Ment Paracrine and Autocrine Functions of Neuronal Vascular Endothelial Growth Factor (VEGF) in the Central Nervous System J. Biol. Chem., March 22, 2002; 277(13): 11410 - 11415. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Arbiser, J. Petros, R. Klafter, B. Govindajaran, E. R. McLaughlin, L. F. Brown, C. Cohen, M. Moses, S. Kilroy, R. S. Arnold, et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch PNAS, January 22, 2002; 99(2): 715 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Guo, L. Xu, S. Pan, R. A. Brekken, S.-T. Yang, G. B. Whitaker, M. Nagane, P. E. Thorpe, J. S. Rosenbaum, H.-J. Su Huang, et al. Vascular Endothelial Growth Factor Isoforms Display Distinct Activities in Promoting Tumor Angiogenesis at Different Anatomic Sites Cancer Res., December 1, 2001; 61(23): 8569 - 8577. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ferrajoli, T. Manshouri, Z. Estrov, M. J. Keating, S. OBrien, S. Lerner, M. Beran, H. M. Kantarjian, E. J. Freireich, and M. Albitar High Levels of Vascular Endothelial Growth Factor Receptor-2 Correlate with Shortened Survival in Chronic Lymphocytic Leukemia Clin. Cancer Res., April 1, 2001; 7(4): 795 - 799. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |